Mirati Therapeutics Inc (NASDAQ:MRTX) – Equities research analysts at B. Riley issued their Q2 2019 earnings per share estimates for shares of Mirati Therapeutics in a report issued on Wednesday, June 19th, Zacks Investment Research reports. B. Riley analyst H. Polishetty forecasts that the biotechnology company will post earnings of ($1.23) per share for the quarter. B. Riley currently has a “Neutral” rating and a $92.00 price target on the stock. B. Riley also issued estimates for Mirati Therapeutics’ Q3 2019 earnings at ($1.29) EPS, Q4 2019 earnings at ($1.33) EPS, FY2019 earnings at ($5.02) EPS, FY2020 earnings at ($5.05) EPS, FY2021 earnings at ($5.89) EPS, FY2022 earnings at ($6.94) EPS and FY2023 earnings at ($5.54) EPS.
Mirati Therapeutics (NASDAQ:MRTX) last announced its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.20). The firm had revenue of $1.24 million during the quarter.
Shares of Mirati Therapeutics stock traded up $0.21 on Friday, reaching $105.71. 265,561 shares of the company were exchanged, compared to its average volume of 582,893. Mirati Therapeutics has a one year low of $28.50 and a one year high of $109.64. The firm has a market cap of $3.80 billion, a P/E ratio of -33.14 and a beta of 2.02. The firm’s 50-day moving average is $95.84.
In related news, Director Michael G. Grey sold 5,760 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $65.30, for a total value of $376,128.00. Following the sale, the director now owns 7,100 shares in the company, valued at approximately $463,630. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bruce L. A. Carter sold 3,000 shares of the stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $75.20, for a total value of $225,600.00. Following the completion of the sale, the director now owns 3,000 shares in the company, valued at approximately $225,600. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,260 shares of company stock worth $1,164,228. 4.86% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of MRTX. CWM LLC acquired a new position in Mirati Therapeutics in the 1st quarter valued at $40,000. Legal & General Group Plc grew its holdings in Mirati Therapeutics by 16.5% in the 4th quarter. Legal & General Group Plc now owns 3,635 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 515 shares in the last quarter. Meeder Asset Management Inc. grew its holdings in Mirati Therapeutics by 7.9% in the 1st quarter. Meeder Asset Management Inc. now owns 2,252 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 165 shares in the last quarter. Creative Planning acquired a new position in Mirati Therapeutics in the 1st quarter valued at $231,000. Finally, Xact Kapitalforvaltning AB acquired a new position in Mirati Therapeutics in the 1st quarter valued at $235,000.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.
See Also: Why are percentage decliners important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.